Methylated, SMD homologous peptides, reactive with the antibodies from sera of living beings affected with systemic lupus erythematosus
US6362007B1 · kind B1 · utility
0Cited by
2References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 10, 1999 |
| Grant date | Mar 26, 2002 |
| Priority date | — |
| Expiry date | May 10, 2019 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a method of producing certain peptides containing methylated arginines that are followed by a glycine residue and that constitute immunogenic determinants of antibodies present in sera from patients with systemic lupus erythematosus, or Epstein-Barr virus and wherein the methylation is a prerequisite for reacting with said antibodies. The invention also relates to the use of said peptides for diagnosis and treatment of systemic lupus erythematosus and related diseases, and diseases in which Epstein-Barr virus has been implicated.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.